Meeting
2023 ASCO Annual Meeting
Not all treated KRAS-mutant pancreatic adenocarcinomas are equal: KRAS G12D and survival outcome.
Authors
Bach Ardalan
Sylvester Comprehensive Cancer Center, Miami, FL
Bach Ardalan , Aaron Ciner , Yasmine Baca , Sourat Darabi , Anup Kasi , Emil Lou , Jose Ignacio Azqueta , Joanne Xiu , Chadi Nabhan , Anthony F. Shields , Andrew Aguirre , Harshabad Singh , Rachna T. Shroff , Michael J. Pishvaian , Sanjay Goel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer - Advanced/Metastatic Disease
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4020)
DOI
10.1200/JCO.2023.41.16_suppl.4020
Abstract #
4020
Poster Bd #
341
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Prognostic indicators of KRAS G12X mutations in pancreatic cancer.
First Author: Bach Ardalan
Poster
2022 ASCO Annual Meeting
Evaluation of stage IV pancreatic adenocarcinomas based on mutational profiling of tumors.
First Author: Katherine E Poruk
Poster
2021 ASCO Annual Meeting
Genomic and immunologic characterization of large-cell neuroendocrine carcinoma of the lung.
First Author: Chul Kim
Poster
2023 ASCO Annual Meeting
The genomic, transcriptomic, and immunological landscape of SGLT2 in lung cancer.
First Author: Heng Tan